India Globalization Capital
Potomac, Maryland, USA 20854

July 26, 2022

Dear Shareholders:

We are excited to report progress on our investigational new drug IGC-AD1 for Alzheimer's disease. The pre-clinical data indicates efficacy against certain hallmarks of the disease, like plaques and tangles in cell lines. However, since we have identified the need for an approved medication to specifically treat agitation in dementia due to Alzheimer's, our immediate current strategy is to focus on assessing the effect of IGC-AD1 on such symptoms.

During our Phase 1 trial, the Company discovered positive signals for improving several neuropsychiatric symptoms including agitation in dementia associated with Alzheimer's. Based on these signals, on April 26, 2022, we filed a multisite protocol with the U.S. Food and Drug Administration ("FDA") to initiate a larger safety and efficacy trial to evaluate IGC-AD1 as a symptom modifying agent, specifically on agitation in dementia due to Alzheimer's disease. The clinical trial process is described in detail in IGC's annual report on Form 10-K, filed with the U.S. Securities and Exchange Commission on June 14, 2021.

The Company recently also acquired rights to a family of naphthalene monoimide ("NMI") molecules. TGR-63, a lead NMI molecule, is an enzyme inhibitor that has been shown in pre-clinical trials to reduce neurotoxicity in Alzheimer's cell lines and improve memory in an Alzheimer's mouse model. Subject to further study, research, and development, TGR-63 could give the Company a potential disease modifying agent wherein IGC-AD1 could serve as a symptom modifying agent. Together, they help expand the Company's pursuit of a drug that can potentially treat or modify Alzheimer's.

In fiscal 2022, the U.S. Patent and Trademark Office issued a patent (#11,065,225) to the University of South Florida for the "Ultra-Low dose THC as a potential therapeutic and prophylactic agent for Alzheimer's Disease," relating to IGC's proprietary formulation, IGC-AD1, intended to assist in the treatment of individuals living with Alzheimer's disease. The Company holds an exclusive license to the patent.

According to the World Health Organization (2020), over 55 million individuals suffer from dementia worldwide, with 60-70% of dementia related to Alzheimer's. This number is projected to increase to about 78 million individuals in 2030, with the estimated total global societal cost of dementia expected to surpass $2.8 trillion by 2030. The Alzheimer's Association ("ALZ") estimates than over 6 million Americans are living with Alzheimer's in 2022 and that this number is projected to rise to nearly 13 million by 2050. The burden of Alzheimer's and other dementias on individuals, caregivers, government, and the U.S.'s health care system is growing exponentially. According to the ALZ, "in 2022, Alzheimer's and other dementias will cost the nation $321 billion." The ALZ believes that by 2050, these costs could increase to about $1 trillion. Moreover, they report that over 11 million Americans care for people with dementias including from Alzheimer's with about "16 billion unpaid hours of care valued at nearly $272 billion."

Eddie Jones et al., (J Alzheimer's Dis 2021) states that "agitation has been reported to be experienced by 60% of patients with mild cognitive impairment and 76% of patients with Alzheimer's disease." If IGC-AD1 is successful in the Phase 2 trial and other future trials and is approved by the FDA as a pharmaceutical drug, it could give the Company a drug with significant potential economic value.

Sincerely,
Ram Mukunda
Chief Executive Officer
India Globalization Capital, Inc. (IGC)